The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

por Lu, Tingting, Huang, Yufan, Cai, Zhongjie, Lin, Wangchun, Chen, Xiaoxiao, Chen, Ruijia, Hu, Yingying
Publicado 2023

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

por He, Ying, Lin, Wangchun, Cai, Zhongjie, Huang, Yufan, You, Maojin, Lei, Meisheng, Chen, Ruijia
Publicado 2023